Please select the option that best describes you:
Topics:
Dermatology • Bullous/Blistering Skin Disorders
How have you applied the findings of this trial to your current approach to prescribing rituximab for pemphigus patients?
Do you have concerns that the 52 week follow up period may be insufficient to capture the full relapse pattern and risk, especially considering published data suggesting that most relapses after rituximab occur around 15-25 months?
Answer from: at Academic Institution
For the MMF vs MMF + Rituximab trial, the patients received two courses of Rituximab six months apart. The B cells don’t start to recover until about six months after the infusions. The data shows more patients in the rituximab group achieved sustained CRoff pred for 15 weeks or more relative to M...
Sign In or Register to read more
Answer from: at Academic Institution
The findings of this trial add support to the body of literature suggesting that non-rheumatologic or hematologic dosing regimens could be considered for pemphigus. However, a few concerns remain, particularly when considering the ultra-low dose cohort. In light of the body of literature highlightin...
Answer from: at Community Practice
52 week followup is below what may be peak for B cell repopulation and while there are too few patients with too short of followup so far, this ULTx may offer 1-lower immune compromise, especially in older populations who may be inherently more at risk, 2- less cost and potential for repeat therapy ...